LAVOUE, V.; HUCHON, C.; AKLADIOS, C.; ALFONSI, P.; BAKRIN, N.; BALLESTER, M.; BENDIFALLAH, S.; BOLZE, P. A.; BONNET, Fabrice; BOURGIN, C.; CHABBERT-BUFFET, N.; COLLINET, P.; COURBIERE, B.; DE LA MOTTE ROUGE, T.; DEVOUASSOUX-SHISHEBORAN, M.; FALANDRY, C.; FERRON, G.; FOURNIER, L.; GLADIEFF, L.; GOLFIER, F.; GOUY, S.; GUYON, F.; LAMBAUDIE, E.; LEARY, A.; LECURU, F.; LEFRERE-BELDA, M. A.; LEBLANC, E.; LEMOINE, A.; NARDUCCI, F.; OULDAMER, L.; PAUTIER, P.; PLANCHAMP, F.; POUGET, N.; RAY-COQUARD, I.; ROUSSET-JABLONSKI, C.; SENECHAL-DAVIN, C.; TOUBOUL, C.; THOMASSIN-NAGGARA, I.; UZAN, C.; YOU, B.; DARAI, E.

doi:10.1016/j.jogoh.2019.03.018

El sistema se apagará debido a tareas habituales de mantenimiento. Por favor, guarde su trabajo y desconéctese.

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

Idioma

Article de revue

Este ítem está publicado en

Journal of gynecology obstetrics and human reproduction. 2019-06, vol. 48, n° 6, p. 379-386

Resumen en inglés

Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).< Leer menos

Palabras clave en inglés

MORPH3Eus